This week, we're inside the reward brain on GLP-1s. Some people describe a welcome quiet, less food noise and fewer cravings, while others describe something harder to name: a flatness where the pleasure used to be. Both stories are real, and the science is only beginning to catch up. ☕

THE BIG ONE

The reward brain on GLP-1s: when the food noise fades, what else does?

"The food noise is gone, which I love. But so is the fun. Wine doesn't sound good, TV doesn't sound good, nothing sounds good. Is this the drug?"

This is the most emotionally loaded question in the GLP-1 forums. It comes in two versions. One group describes a welcome quiet: less rumination, less anxiety, alcohol cravings vanishing overnight. Another describes flatness, a muting of pleasure that goes beyond food. Both are real reports. Here's what the science can and can't say.

GLP-1 RECEPTORS AND THE REWARD SYSTEM

The same receptors semaglutide (Wegovy, Ozempic; FDA-approved for weight management and type 2 diabetes) and tirzepatide (Zepbound, Mounjaro; FDA-approved for weight management and type 2 diabetes) act on in the gut and appetite centers are also found in the brain's reward circuitry, the regions involved in wanting and enjoying things. Neither drug is approved for any mood, anxiety, or addiction indication; use for those purposes remains investigational. Dampen reward signaling and food loses its pull. Dampen it further, or in a different person, and other things might too. It's also why the VA is currently trialing GLP-1s for alcohol use disorder. "The fun is gone" is not a far-fetched thing to say. It's an understudied one.

WHAT REGULATORS FOUND

When reports of suicidal thoughts surfaced in 2023, European and US regulators both reviewed the data and both concluded the evidence did not support a causal link. Large observational studies since have pointed, if anything, toward lower rates of suicidal ideation on GLP-1s than on comparison drugs. That's reassuring on the most serious question. It says nothing about anhedonia, which nobody has studied directly.

WHY THE ANSWER IS THINNER FOR WOMEN

Women are diagnosed with depression and anxiety at roughly twice the rate of men. The STEP trials excluded anyone with moderate-to-severe depression symptoms or any history of suicide attempt. So the women most likely to be asking "is this the drug or is this me" were largely not in the trials that approved them. And perimenopause and postpartum, two of the most common seasons for GLP-1 use, bring their own mood changes on the same calendar.

THE FEMALE DATA GAP

The women with the most reason to ask about mood on these drugs were the ones not enrolled in the trials that approved them.

DEINFLUENCED

WHAT THE EVIDENCE SAYS

There is nothing in semaglutide or tirzepatide that targets facial tissue. What people are calling "Ozempic face" is what significant, fast weight loss has always done: facial fat leaves along with everything else, and in adults over 40 the skin above it has less collagen to bounce back with. The same look appears after bariatric surgery and aggressive dieting. It just didn't have a catchy name then.

The phrase matters because it reframes an expected consequence of losing weight quickly as a reason to fear one specific drug. Women in the forums are worrying about it before they've lost a pound.

ASK A CLINICIAN

It might be, and it's worth taking seriously either way. These medications act on parts of the brain involved in reward and motivation, and some people describe exactly what you're describing. It isn't a listed side effect, and no study has measured it directly, so there isn't a clear clinical answer yet.

What a prescriber can help with: noting when the flatness started, whether it tracks with the medication timeline, and whether other factors like sleep, stress, or hormonal shifts might also be contributing. That kind of pattern is useful clinical information, and a provider can only act on what they hear.

One more thing worth saying plainly: if the flatness ever includes thoughts of harming yourself, that is a now situation, not a next-appointment one. In the US, 988 is available by call or text.

ON THE RADAR

This issue was medically reviewed by Mais, PharmD.
Pep in Her Step is education, not medical advice.
Talk to your prescriber before doing anything peptide-shaped.
We don't sell peptides and never will.

Forwarded this? Get it weekly at pepinherstep.com